Amphastar Pharmaceuticals Announces Pricing of Initial Public Offering

RANCHO CUCAMONGA, Calif., June 25, 2014 -- Amphastar Pharmaceuticals, Inc. (Amphastar) (AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and inhalation products, today announced the pricing of its initial public offering of 8,000,000 shares of its common stock, including 3,360,000 shares from the selling stockholder named in the registration statement, at an initial public offering price of $7.00 per share for a total offering amount of $56,000,000 before deducting underwriting discounts and commissions, and estimated offering expenses payable by Amphastar. Amphastar will not receive any proceeds from the sale of the shares by the selling stockholder. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the initial public offering price. The shares are expected to begin trading on The NASDAQ Global Select Market on June 25, 2014 under the symbol "AMPH."

Aerie Pharmaceuticals Reports RoclatanTM Phase 2b Results Achieve All Clinical Endpoints

Once-Daily Product Shows Potential to Be Highest Efficacy IOP-Lowering Therapy
Quadruple-Action Product for Glaucoma Patients
Conference Call and Webcast Today, June 25, at 8:00 a.m. ET

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.-- Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action Roclatan^TM, a combination of Aerie’s triple-action Rhopressa^TM with latanoprost, a prostaglandin analogue (PGA). Management will host a conference call to discuss these results at 8:00 a.m. ET today.

CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA

BRIDGEWATER, N.J., June 23, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin® for use in hemodialysis patients with a central venous catheter.  CorMedix worked with the FDA to develop the protocol design for the planned trial for a marketing application.  Based on FDA input, the planned Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe.  Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4

NEW YORK, June 24, 2014  -- TG Therapeutics, Inc. (TGTX), announced today an agreement with Ligand Pharmaceuticals Incorporated (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. Interleukin-1 Receptor Associated Kinase 4, referred to as IRAK4, is a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldenstrom's Macroglobulinemia, a rare B-cell cancer, as well as in a sub-set of patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Additionally, IRAK4 is a key component of signaling pathways which regulate immune and inflammatory processes suggesting that inhibition of IRAK4 may also be useful in the treatment of autoimmune related disorders. The IRAK4 program is currently in pre-clinical development.